News - GW Pharmaceuticals, Financial

Filter

Popular Filters

GW Pharma revenues rise but 1st-qtr loss incurred

GW Pharma revenues rise but 1st-qtr loss incurred

05-02-2014

Shares of UK-based cannabis-based drug developer GW Pharmaceuticals fell 3,9% to 287.39 pence this morning,…

epidiolexFinancialGW PharmaceuticalsNeurologicalPharmaceuticalResearchSativex

GW Pharma sees fiscal 2012/3 revenues decline, impacted by Sativex

GW Pharma sees fiscal 2012/3 revenues decline, impacted by Sativex

19-11-2013

UK-based GW Pharmaceuticals (AIM: GWP) which is focused on novel cannaboid therapeutics, has announced…

CNS DiseasesFinancialGW PharmaceuticalsPharmaceuticalSativexUK

GW Pharma goes into 3rd-qtr loss

05-08-2013

UK-based GW Pharmaceuticals (Nasdaq: GWPH, AIM: GWP) which is focused on discovering, developing and…

FinancialGW PharmaceuticalsPharmaceuticalSativex

GW Pharma posts six-month results; progresses cannabinoid pipeline including into diabetes and UC

05-06-2013

UK biopharma company GW Pharmaceuticals (AIM: GWP), which is developing and commercializing novel therapeutics…

DiabetesFinancialGastro-intestinalsGW PharmaceuticalsNeurologicalPharmaceuticalResearchSativex

Almirall pays GW Pharma milestone on Sativex; reports 1st-qtr results

07-05-2013

UK-based GW Pharmaceuticals (AIM: GWP) says that it has received commercialization approval for its cannabinoid-based…

AlmirallEuropeFinancialGW PharmaceuticalsNeurologicalPharmaceuticalRegulationSativex

Spanish reforms and generics hit Almirall's 1st-qtr; Sativex progress

09-05-2012

Spain's leading drugmaker Almirall (ALM: MC) has reported a 5.9% decrease in sales for the first quarter…

AlmirallEuropeFinancialGW PharmaceuticalsNeurologicalPharmaceuticalRegulationSativex

GW Pharma and Almirall extend Sativex deal to Mexico

15-03-2012

UK-based GW Pharmaceuticals (AIM: GWP) announces that it has signed an amendment to its cannabis-based…

AlmirallFinancialGW PharmaceuticalsLicensingNeurologicalPharmaceuticalSativexSouth America

Back to top